首页> 外文期刊>Radiochimica Acta: International Journal for Chemical Aspects of Nuclear Science and Technology >Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in beast carcinoma xenografts
【24h】

Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in beast carcinoma xenografts

机译:放射性镧标记的卟啉复合物在兽癌异种移植中可能作为治疗剂的开发

获取原文
获取原文并翻译 | 示例
       

摘要

Radiolabeled porphyrins are potential tumor avid radiopharmaceuticals because of their behaviour in the human body, ability to complex various radionuclides, water solubility, low toxicity etc., in this work radio ytterbium/samarium porphyrin complexes have been developed. ~(175)Yb and ~(153)Sm labeled 5,10,15,20-tetrakis(3,4-dimethoxyphenyl) porphyrins ([~(175)Yb]-TDMPP/[~(153)Sm]-TDMPP) were prepared using 5,10,15,20-tetrakis(3,4-dimethoxyphenyl) porphyrin (H_2TDMPP) and [~(175)Yb]YbCl_3 or [~(153)Sm]SmCl_3 in 12-24 h at 60 °C. Stability of the complexes were checked in final formulation and human serum for 24 h, followed by partition coefficient determination and biodistribution studies in wild type and breast carcinoma-bearing mice. The radiocomplexes were obtained with acceptable radiochemical purity (> 95% (paper chromatography) and > 96% (HPLC) for [~(175)Yb]-TDMPP and > 97% (paper chromatography) and >98% (HPLC) for [~(153)Sm]-TDMPP) with specific activities of 12-15 GBq/mmol and 278 GBq/mmol at the end of bombardment for [~(175)Yb]-TDMPP and [~(153)Sm]-TDMPP respectively. The partition coefficients were determined for [~(175)Yb]-TDMPP and [~(153)Sm]-TDMPP) (logP = 0.63 and log P = 0.96 respectively). The [~(175)Yb]-TDMPP complex is mostly washed out from the circulation through kidneys. Liver and spleen also demonstrated significant activity uptake in 72 h post injection. Also [~(153)Sm]-TDMPP, is mostly washed out from the circulation through kidneys, however lungs are the major accumulation sites. The [~(153)Sm]-TDMPP complex demonstrated significant targeted uptake in breast carcinoma xenografts with tumor: blood ratios of 10.67, 10.47 and 19.01 in 24, 48 and 72 h respectively. Also interesting tumor: kidney/liver ratios were obtained. ~(153)Sm-TDMPP properties suggest an efficient tumor targeting agent with high tumor-avidity. Further investigation on the therapeutic properties must be conducted.
机译:放射性标记的卟啉是潜在的肿瘤狂热放射性药物,因为它们在人体中的行为,与各种放射性核素的络合能力,水溶性,低毒性等,在这项工作中,已经开发了放射性/ mar卟啉络合物。 〜(175)Yb和〜(153)Sm标记为5,10,15,20-四(3,4-二甲氧基苯基)卟啉([〜(175)Yb] -TDMPP / [〜(153)Sm] -TDMPP)使用5,10,15,20-四(3,4-二甲氧基苯基)卟啉(H_2TDMPP)和[〜(175)Yb] YbCl_3或[〜(153)Sm] SmCl_3在60°C下于12-24小时制得。在最终制剂和人血清中检查复合物的稳定性24小时,然后在野生型和乳腺癌小鼠中进行分配系数测定和生物分布研究。获得的放射性配合物具有可接受的放射化学纯度(对于[〜(175)Yb] -TDMPP,> 95%(纸色谱)和> 96%(HPLC),对于[[75] Yb] -TDMPP> 97%(纸色谱)和> 98%(HPLC) 〜(153)Sm] -TDMPP)在轰击结束时对[〜(175)Yb] -TDMPP和[〜(153)Sm] -TDMPP的比活分别为12-15 GBq / mmol和278 GBq / mmol 。确定[〜(175)Yb] -TDMPP和[〜(153)Sm] -TDMPP)的分配系数(分别为logP = 0.63和log P = 0.96)。 [〜(175)Yb] -TDMPP复合物大部分从肾脏循环中被冲走。肝和脾在注射后72小时也显示出显着的活动摄取。 [[((153)Sm] -TDMPP]大部分也被从肾脏的循环系统中清除掉,但是肺是主要的蓄积部位。 [〜(153)Sm] -TDMPP复合物在乳腺癌异种移植物中的肿瘤:血液比率分别为24、48和72 h分别为10.67、10.47和19.01,表现出显着的靶向摄取。还获得了有趣的肿瘤:肾脏/肝脏比率。 〜(153)Sm-TDMPP性质表明具有高肿瘤亲和力的有效肿瘤靶向剂。必须对治疗性能进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号